Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Joan Mannick on Rapamycin Longevity Series | Turning down mTOR to young levels may be good for aging

Joan Mannick on Rapamycin Longevity Series | Turning down mTOR to young levels may be good for aging

FromMaster One Thing - Rapamycin Longevity Series


Joan Mannick on Rapamycin Longevity Series | Turning down mTOR to young levels may be good for aging

FromMaster One Thing - Rapamycin Longevity Series

ratings:
Length:
82 minutes
Released:
Jan 17, 2024
Format:
Podcast episode

Description

Dr Joan Mannick is one of the world’s leading rapamycin and mTOR researchers in the longevity field. Joan has a background in academic medicine and is currently CEO at her own company Tornado Therapeutics where they focus on developing the next generation of mTOR inhibitors. One of the company goals is to create a mTOR inhibitor which is better than Rapamycin. Throughout the years Joan has made important discoveries in humans when it comes to finding a connection between mTOR inhibition and improvement of the aging immune system. In this podcast we are going to talk about her research, drug development, mTOR, rapamycin, rapalogs and other interesting longevity topics.Linkshttps://www.tornado-tx.comJoan's LinkedInJoan’s research publicationsBig thanks to TimePie for the research help for this episodeRapamycin resourcesRapamycin.newsRapamycin Facebook groupRapamycin Reddit groupConnect with Krister on:TwitterLinkedInInstagramDisclaimer: The podcast is for general information and educational purposes only and is not medical advice for you or others. The use of information and materials linked to the podcast is at the users own risk. Always consult your physician with anything you do regarding your health or medical condition.
Released:
Jan 17, 2024
Format:
Podcast episode